TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Neuromuscular Electrical Stimulation For Quadriceps Muscle Activation Deficits Following Total Knee Replacement
Brief Summary: The purpose of this study is to determine whether early intervention with neuromuscular electrical stimulation (NMES) for muscle strengthening immediately after total knee arthroplasty (TKA) is more effective than voluntary exercise alone in countering changes in quadriceps muscle activation, force production, and function in older adults.


Options:
A: Arm Label: No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Electrical Stimulation; Type: EXPERIMENTAL; Interventions: Device: Electrical Stimulation | Intervention Type: DEVICE; Name: Electrical Stimulation; Assigned to Arm(s): Electrical Stimulation
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Device: neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB) | Arm Label: B; Type: SHAM_COMPARATOR; Interventions: Device: neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB) | Intervention Type: DEVICE; Name: neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB); Assigned to Arm(s): A | Intervention Type: DEVICE; Name: neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB); Assigned to Arm(s): B
C: Arm Label: ES; Type: ACTIVE_COMPARATOR; Interventions: Device: Electrostimulation | Arm Label: Sham ES; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham stimulation | Intervention Type: DEVICE; Name: Electrostimulation; Assigned to Arm(s): ES | Intervention Type: DEVICE; Name: Sham stimulation; Assigned to Arm(s): Sham ES
D: Arm Label: Neuromuscular Electrical Stimulation (NMES); Type: EXPERIMENTAL; Interventions: Device: Neuromuscular Electrical Stimulation (NMES) | Arm Label: Standard Rehabilitation Protocol; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Rehabilitation Protocol | Intervention Type: DEVICE; Name: Neuromuscular Electrical Stimulation (NMES); Assigned to Arm(s): Neuromuscular Electrical Stimulation (NMES) | Intervention Type: OTHER; Name: Standard Rehabilitation Protocol; Assigned to Arm(s): Standard Rehabilitation Protocol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Randomized Diabetes Intervention Among Inner-city African American and Latino Adults
Brief Summary: The objectives of the proposed study are to determine whether culturally diverse community residents with diabetes are willing to participate in our community health worker intervention using randomized controlled trial (RCT) methods and to explore and document effective processes and protocols for RCT methods in these communities. The investigators will examine retention rates, identify reasons for attrition through interviews and focus groups, and determine strategies for improving recruitment, retention, and intervention methods. As a secondary objective, the investigators will explore the potential impacts of the intervention for improving healthy lifestyles, diabetes self-management, and selected health outcomes of participants.


Options:
A: Arm Label: Shared Decision Making/Brief Negotiated Interviewing; Type: OTHER; Interventions: Behavioral: Shared Decision Making | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shared Decision Making; Assigned to Arm(s): Shared Decision Making/Brief Negotiated Interviewing
B: Arm Label: Information on community resources; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Community Health Worker services; Type: EXPERIMENTAL; Interventions: Behavioral: Community Health Worker (CHW) services | Intervention Type: BEHAVIORAL; Name: Community Health Worker (CHW) services; Assigned to Arm(s): Community Health Worker services
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Physician-pharmacist collaborative intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physician-pharmacist collaborative intervention; Assigned to Arm(s): 1
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored cardiovascular risk management (Nurse-administered ) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tailored cardiovascular risk management (Nurse-administered ); Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Randomized Diabetes Intervention Among Inner-city African American and Latino Adults
Brief Summary: The objectives of the proposed study are to determine whether culturally diverse community residents with diabetes are willing to participate in our community health worker intervention using randomized controlled trial (RCT) methods and to explore and document effective processes and protocols for RCT methods in these communities. The investigators will examine retention rates, identify reasons for attrition through interviews and focus groups, and determine strategies for improving recruitment, retention, and intervention methods. As a secondary objective, the investigators will explore the potential impacts of the intervention for improving healthy lifestyles, diabetes self-management, and selected health outcomes of participants.


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer Automated Self-Management (CASM) | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer Automated Self-Management (CASM), Behavioral: Computer Automated Self-Management and Problem Solving Therapy (CAPS) | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle and Activities Education Program (LEAP-AHEAD) | Intervention Type: BEHAVIORAL; Name: Lifestyle and Activities Education Program (LEAP-AHEAD); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Computer Automated Self-Management (CASM); Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Computer Automated Self-Management and Problem Solving Therapy (CAPS); Assigned to Arm(s): 3
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Breaking Down Barriers | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Breaking Down Barriers | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Breaking Down Barriers | Intervention Type: BEHAVIORAL; Name: Breaking Down Barriers; Assigned to Arm(s): 1, 2, 3
C: Arm Label: Information on community resources; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Community Health Worker services; Type: EXPERIMENTAL; Interventions: Behavioral: Community Health Worker (CHW) services | Intervention Type: BEHAVIORAL; Name: Community Health Worker (CHW) services; Assigned to Arm(s): Community Health Worker services
D: Arm Label: Geriatric Diabetes Team Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral | Arm Label: Atention Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral; Assigned to Arm(s): Geriatric Diabetes Team Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 vs. Placebo, DB, Parallel Group, Randomized, Insulin Background Inclusive
Brief Summary: to determine safety, efficacy and tolerability of BI 1356 versus placebo


Options:
A: Arm Label: Sitagliptin; Type: EXPERIMENTAL; Interventions: Drug: Sitagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: BI 1356; Type: EXPERIMENTAL; Interventions: Drug: BI 1356 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Treatment A; Type: EXPERIMENTAL; Interventions: Drug: LX4211 | Arm Label: LX4211 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: LX4211 Placebo | Intervention Type: DRUG; Name: LX4211; Assigned to Arm(s): Treatment A | Intervention Type: DRUG; Name: LX4211 Placebo; Assigned to Arm(s): LX4211 Placebo
D: Arm Label: Saxagliptin 2.5 mg (A); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Saxagliptin 5 mg (B); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Saxagliptin 10 mg (C); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Placebo (D); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matching Saxagliptin, Drug: Metformin | Arm Label: Open-Label Treatment Cohort (Direct Enrollees) (E); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 2.5 mg (A) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 5 mg (B) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 10 mg (C) | Intervention Type: DRUG; Name: Placebo matching Saxagliptin; Assigned to Arm(s): Placebo (D) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Placebo (D) | Intervention Type: DRUG; Name: Placebo matching Metformin; Assigned to Arm(s): Saxagliptin 10 mg (C), Saxagliptin 2.5 mg (A), Saxagliptin 5 mg (B) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Open-Label Treatment Cohort (Direct Enrollees) (E) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Open-Label Treatment Cohort (Direct Enrollees) (E), Placebo (D), Saxagliptin 10 mg (C), Saxagliptin 2.5 mg (A), Saxagliptin 5 mg (B)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Cholesterol Lowering on the Progression of Aortic Stenosis in Patients With Mild to Moderate Aortic Stenosis (ASTRONOMER)Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin and The Sub-Study Protocol.
Brief Summary: The purpose of this study is to assess the effects of rosuvastatin compared to usual care in patients diagnosed with aortic valvular stenosis. Patients must have a diagnosis of mild to moderate aortic stenosis (AS) and no clinical indication for the use of cholesterol lowering agents. A multi-centre, randomized, double-blind, placebo-controlled study, with a two year recruitment period, and a treatment duration of a minimum of 3 years from the time of the last patient randomized to a maximum of 5 years.


Options:
A: Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): N/A
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Simvastatin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Simvastatin | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: ABT-335, Drug: Placebo | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Arm Label: E; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Arm Label: F; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: ABT-335; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): A, B, D, E, F | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): C, D, E, F
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: rosuvastatin calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Vyvanse on the Driving Performance of Young Adults With ADHD: A Randomized, Double-Blind, Placebo-Controlled Study
Brief Summary: The primary objective of the study is to assess the benefice of Vyvanse on the factors that cause impairments in driving behavior in individuals with ADHD using a driving simulation aimed at examining the factors that cause impairments in driving behavior in individuals with ADHD such as driving speed, collision risk, and visual attention of 60 young drivers (ages 18-24) with ADHD. We hypothesize: 1.) young adults with ADHD treated with Vyvanse will show lower velocity (speed) scores and spend less time driving over the posted speed limit in the driving simulation when compared to subjects taking a placebo; 2.) young adults with ADHD treated with Vyvanse will show a lesser likelihood to collide with a suddenly appearing peripheral object, less difficulty maintaining the vehicle within their lane, and a lesser likelihood of driving through stop signs and solid red traffic lights without slowing down when compared to subjects taking a placebo; and 3.) young adults with ADHD treated with Vyvanse will exhibit more focused visual attention on details in the visual field when compared to subjects taking a placebo while driving. In addition, young adults with ADHD treated with Vyvanse will exhibit less visual tunneling and shorter off-road glances when compared to subjects taking a placebo.


Options:
A: Arm Label: LDX Treatment; Type: EXPERIMENTAL; Interventions: Drug: LDX Treatment | Intervention Type: DRUG; Name: LDX Treatment; Assigned to Arm(s): LDX Treatment
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: NRP104 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: NRP104 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: NRp104 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NRP104; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: NRP104; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: NRp104; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
C: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A
D: Arm Label: Vyvanse; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vyvanse | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vyvanse; Assigned to Arm(s): Vyvanse | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One or More Cycles in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy
Brief Summary: The purpose of this uncontrolled, multi-center, open-label trial was to investigate the feasibility of using degarelix as intermittent androgen deprivation (IAD) therapy in the treatment of prostate cancer.


Options:
A: Arm Label: Degarelix 240 mg / 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Degarelix 240 mg / 80 mg | Intervention Type: DRUG; Name: Degarelix 240 mg / 80 mg; Assigned to Arm(s): Degarelix 240 mg / 80 mg
B: Arm Label: Degarelix; Type: EXPERIMENTAL; Interventions: Drug: Degarelix | Arm Label: Degarelix + Casodex; Type: EXPERIMENTAL; Interventions: Drug: Degarelix, Drug: Casodex | Arm Label: LHRH Agonist + Casodex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Casodex, Drug: LHRH Agonist | Intervention Type: DRUG; Name: Degarelix; Assigned to Arm(s): Degarelix, Degarelix + Casodex | Intervention Type: DRUG; Name: Casodex; Assigned to Arm(s): Degarelix + Casodex, LHRH Agonist + Casodex | Intervention Type: DRUG; Name: LHRH Agonist; Assigned to Arm(s): LHRH Agonist + Casodex
C: Arm Label: Degarelix 240 mg/80 mg; Type: EXPERIMENTAL; Interventions: Drug: Degarelix | Arm Label: Goserelin (3.6 mg) + bicalutamide (50 mg); Type: ACTIVE_COMPARATOR; Interventions: Drug: Goserelin, Drug: Bicalutamide | Intervention Type: DRUG; Name: Degarelix; Assigned to Arm(s): Degarelix 240 mg/80 mg | Intervention Type: DRUG; Name: Goserelin; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg) | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg)
D: Arm Label: ASP3550 PART 1 and PART 2; Type: EXPERIMENTAL; Interventions: Drug: degarelix | Arm Label: Goserelin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Goserelin | Intervention Type: DRUG; Name: degarelix; Assigned to Arm(s): ASP3550 PART 1 and PART 2 | Intervention Type: DRUG; Name: Goserelin; Assigned to Arm(s): Goserelin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Oily Fish in Pregnancy on Markers and Manifestations of Allergic Diseases in Infants at Risk of Atopy
Brief Summary: The number of infants and children with allergic disease (dermatitis, allergies, asthma) has increased over the last several decades. This may be related to changes in diet. It is now thought that children become sensitised to allergens very early in life maybe even before they are born. Some studies show that a high omega-3 fat intake by mothers decreases risk of sensitisation in their babies. There is a biological mechanism to explain this. Omega-3 fats are found in oily fish like salmon. In the UK pregnant women are recommended to eat oily fish twice per week. However, consumption of oily fish is known to be low in pregnant women in the UK. This study sets out to identify the effects of increasing salmon intake in pregnant women. The hypothesis being investigated is that : increased consumption of oily fish during pregnancy by women at risk of having offspring who will develop atopy will increase their omega-3 fat and antioxidant status and that of their developing baby and will ameliorate the development of atopic markers and manifestations in the infants.


Options:
A: Arm Label: Omega-3 polyunsaturated fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Omega-3 polyunsaturated fatty acids | Arm Label: olive oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Olive oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 polyunsaturated fatty acids; Assigned to Arm(s): Omega-3 polyunsaturated fatty acids | Intervention Type: DIETARY_SUPPLEMENT; Name: Olive oil; Assigned to Arm(s): olive oil
B: Arm Label: 17P plus Omega-3 Supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement | Arm Label: 17P plus Placebo Supplement; Type: PLACEBO_COMPARATOR; Interventions: Drug: 17 alpha-hydroxy progesterone caproate and Placebo supplement | Intervention Type: DRUG; Name: 17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement; Assigned to Arm(s): 17P plus Omega-3 Supplement | Intervention Type: DRUG; Name: 17 alpha-hydroxy progesterone caproate and Placebo supplement; Assigned to Arm(s): 17P plus Placebo Supplement
C: Arm Label: Control; Type: OTHER; Interventions: Other: Control | Arm Label: Oily fish; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Oily fish consumption | Intervention Type: DIETARY_SUPPLEMENT; Name: Oily fish consumption; Assigned to Arm(s): Oily fish | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
D: Arm Label: Docosa Hexaenoic Acid (DHA); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Docosa Hexaenoic Acid (DHA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Docosa Hexaenoic Acid (DHA); Assigned to Arm(s): Docosa Hexaenoic Acid (DHA) | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Oily Fish in Pregnancy on Markers and Manifestations of Allergic Diseases in Infants at Risk of Atopy
Brief Summary: The number of infants and children with allergic disease (dermatitis, allergies, asthma) has increased over the last several decades. This may be related to changes in diet. It is now thought that children become sensitised to allergens very early in life maybe even before they are born. Some studies show that a high omega-3 fat intake by mothers decreases risk of sensitisation in their babies. There is a biological mechanism to explain this. Omega-3 fats are found in oily fish like salmon. In the UK pregnant women are recommended to eat oily fish twice per week. However, consumption of oily fish is known to be low in pregnant women in the UK. This study sets out to identify the effects of increasing salmon intake in pregnant women. The hypothesis being investigated is that : increased consumption of oily fish during pregnancy by women at risk of having offspring who will develop atopy will increase their omega-3 fat and antioxidant status and that of their developing baby and will ameliorate the development of atopic markers and manifestations in the infants.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Dietary Supplement: omega 3 fatty acids | Arm Label: 2; Type: OTHER; Interventions: Dietary Supplement: vegetable oil | Intervention Type: DIETARY_SUPPLEMENT; Name: omega 3 fatty acids; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: vegetable oil; Assigned to Arm(s): 2
B: Arm Label: DHA arm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: DHA | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA; Assigned to Arm(s): DHA arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo arm
C: Arm Label: Control; Type: OTHER; Interventions: Other: Control | Arm Label: Oily fish; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Oily fish consumption | Intervention Type: DIETARY_SUPPLEMENT; Name: Oily fish consumption; Assigned to Arm(s): Oily fish | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
D: Arm Label: fish oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fish oil | Arm Label: folate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: folate | Arm Label: fish oil + folate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fish oil + folate | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: fish oil; Assigned to Arm(s): fish oil | Intervention Type: DIETARY_SUPPLEMENT; Name: folate; Assigned to Arm(s): folate | Intervention Type: DIETARY_SUPPLEMENT; Name: fish oil + folate; Assigned to Arm(s): fish oil + folate | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): placebo

Answer: C